AbCellera Biologics Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Legal Proceedings
In the pending matter Sabariah Schrader, Executrix of the Estate of John William Schrader et al. v. Carl Lars Genghis Hansen, et al., the Company filed a Notice of Application seeking to dismiss certain Company affiliates from the matter. No hearing date has been set. The Company recently obtained consent to the invalidation of the Immvivos '511 patent and removal of patent infringement allegations. The Company believes that Plaintiffs’ remaining claim is meritless in all respects and intends to defend itself appropriately.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.